U.S. Construction Stock News

Taysha Gene Therapies stock has delivered a very strong 231.9% return over the past three years, yet current valuation checks and market multiples point to a less straightforward picture of whether the recent gains leave enough room for upside from here. The stock is up 231.9% over three years, which puts extra weight on whether recent optimism about its gene therapy pipeline is already reflected in the share price. Progress on TSHA-102 for Rett syndrome, including completed dosing in key...

IDEXX Laboratories has had a weak run over the past five years, yet the current checks suggest the stock is not obviously cheap, with the Discounted Cash Flow (DCF) estimate pointing to a price close to intrinsic value while market multiples lean expensive. That mix leaves investors weighing a fairly valued intrinsic view against richer headline valuation ratios. IDEXX Laboratories has delivered a decline of 15.7% over five years, which softens the long term return story even before looking...

People (PPLI) is in focus after its second quarter results showed higher profitability alongside modestly lower sales, with investors also weighing fresh 2026 guidance, new leadership appointments and ongoing interest in its digital and AI initiatives. See our latest analysis for People. Despite the strong Q2 profit figures and leadership updates, People’s 30 day share price return is down 11.55%, while the 1 year total shareholder return of 13.95% points to longer term momentum that is still...

In August 2026, Helios Technologies, Inc. reported second-quarter sales of US$231.9 million and net income of US$21.9 million, then raised its full-year 2026 sales guidance to a range of US$880 million to US$900 million alongside new third-quarter sales guidance of US$215 million to US$222 million. Management also declared its two-year business stabilization plan complete, signaling a shift to a “takeoff” phase that includes targeting data center thermal management as a major growth...

Global Payments Inc. reported past second-quarter 2026 results showing sales of US$3,320.79 million but net income of just US$12.97 million, alongside sharply lower earnings per share compared with a year earlier. Despite the weaker profitability and a net loss of about US$1.79 billion over the first half of 2026, the board still approved a US$0.25 per share dividend payable on September 25, 2026, underscoring a commitment to ongoing shareholder payouts. Next, we’ll examine how the weaker...

Why Oppenheimer Holdings Stock Is Back in Focus After Q2 Results Oppenheimer Holdings (OPY) moved back onto investor watchlists after reporting second quarter 2026 earnings that showed higher revenue and net income versus a year earlier, alongside an affirmed quarterly dividend. See our latest analysis for Oppenheimer Holdings. The 1 day share price return of 1.47% to US$114.81 came after Oppenheimer Holdings reported higher second quarter revenue and earnings. This follows a 90 day share...

In August 2026, Valvoline Inc. reported its third-quarter results, with sales rising to US$544.6 million and net income reaching US$64.5 million, while also posting higher basic and diluted earnings per share from continuing operations than a year earlier. Despite stronger third-quarter performance, the company’s net income for the first nine months fell to US$76.5 million even as sales increased to US$1.51 billion, highlighting a contrast between recent quarterly momentum and weaker...

Invesco stock has delivered a strong 133.2% return over the past three years, while the intrinsic value estimate from the Excess Returns model points to upside and the market multiple view suggests the shares trade on the expensive side. That split leaves investors weighing a mixed valuation picture rather than a clear bargain or obvious overpricing. Over the past three years, Invesco has returned 133.2%, which puts recent gains at the center of any valuation call on the stock. Expectations...

Marathon Petroleum stock has delivered a very large 5 year return, yet the latest valuation checks suggest the current share price around US$348 is closer to fair value than a clear bargain based on the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples. Over the past 5 years, Marathon Petroleum has returned roughly 7x an initial investment. This puts extra focus on whether recent gains are already pricing in much of the good news. The sharp improvement in refining...

In August 2026, Alpha Metallurgical Resources, Inc. reported second-quarter 2026 results showing revenue of US$492.86 million, down from US$550.27 million a year earlier, and a net loss of US$12.25 million versus US$4.95 million, with basic and diluted loss per share from continuing operations widening to US$0.96 from US$0.38. For the first half of 2026, however, revenue declined modestly to US$1,017.84 million from US$1,082.23 million while the net loss narrowed to US$23.28 million from...

Smithfield Foods stock has fallen around 9.9% over the past week, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples still point to the shares trading below what the fundamentals suggest. The share price declined about 9.9% over the last seven days, which has made the recent valuation gap to intrinsic value more pronounced. The key upside driver is the market's view on Smithfield Foods' ability to keep converting revenue into reliable cash flows. Any...

Dianthus Therapeutics (DNTH) has drawn fresh attention after reporting a second quarter net loss of US$50.22 million and unveiling DNTH312, a first in class bifunctional fusion protein targeting autoimmune disease pathways. See our latest analysis for Dianthus Therapeutics. The latest DNTH312 announcement and second quarter update come after a period of strong momentum in Dianthus Therapeutics’ stock, with a 30 day share price return of 13.96% and a 90 day share price return of 31.72%. The...

Q2 2026 earnings put Humacyte stock back in focus Humacyte (HUMA) has moved back into the spotlight after reporting second quarter 2026 results, with modest revenue and a sizeable quarterly loss prompting investors to reassess the stock’s risk and potential. See our latest analysis for Humacyte. The Q2 2026 loss, the recent Nasdaq minimum bid price notice and the interim Phase III dialysis data have all landed against a weak backdrop for Humacyte. The stock has a 1 day share price return of...

With real wages squeezed by stubborn inflation and household budgets under pressure, investors are paying closer attention to companies tied to everyday essentials. Consumer staples stocks in our U.S. screener sit right in the middle of this story, where price sensitivity, volume trends and cost control all matter. This article walks through 3 stocks that appear positively exposed to this backdrop and explains why each might deserve a place on your watchlist. The stocks covered below are only...

Inflation is cooling but not gone, the Fed looks cautious, and everyday costs from flights to food keep squeezing household budgets. That mix can push shoppers toward discount and value-focused brands, which may help some stocks tied to this trend while leaving others exposed to pressure. This article looks at three stocks linked to the recent CPI backdrop and explains how the same data can create very different stories for investors. The three stocks below are just a starting sample, and the...

Oceaneering International has delivered a very strong 336.8% return over the past 5 years, yet its valuation checks and market signals now suggest the stock may no longer be an obvious bargain, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to a price that is close to where the shares currently trade. A 336.8% total return over 5 years highlights how much value the market has already priced into Oceaneering International, which raises the bar for any...

In early August 2026, McKesson Corporation reported first-quarter sales of US$105.38 billion, up from US$97.83 billion a year earlier, while net income fell to US$614 million and diluted EPS from continuing operations declined to US$5.15 from US$6.25. Over the same quarter, McKesson repurchased 3,600,000 shares for US$2,896.30 million, bringing total buybacks under its long-running program to 70,100,000 shares for US$23,475.49 million, significantly shrinking its share count and reshaping...

Sionna Therapeutics (SION) is back in focus after reporting Phase 2a data showing that lead cystic fibrosis candidate SION-719 missed its key efficacy endpoint as an add-on to Trikafta, prompting the company to halt development. See our latest analysis for Sionna Therapeutics. The failed Phase 2a readout for SION-719 has been followed by sharp share price volatility, with Sionna Therapeutics’ stock down 86.8% on a 7 day share price return and 84.1% on a year to date share price return, while...

NNN REIT has delivered a 40.2% return over the past three years, and the current share price of US$45.81 still screens as cheap relative to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model and traditional multiples. The 40.2% gain over three years suggests investors have already seen solid value creation, yet current indicators still point to room between price and estimated worth. Future cash flows from long term, triple net leases can support this valuation view...

PENN Entertainment has put long term shareholders through a rough ride, with the share price down about 71% over the past 5 years, yet the stock now screens as cheap on several valuation checks. Recent news around stronger physical casino performance and increased iGaming investment has refocused attention on whether the current price reflects the company’s mix of mature retail assets and a more competitive online business. The roughly 71% share price decline over 5 years leaves PENN...

In August 2026, Clarivate Plc expanded agentic AI capabilities across its Cortellis life sciences portfolio, embedding AI into drug discovery, safety assessment and portfolio decision workflows to reduce manual effort and support faster, evidence-based decisions. By integrating multi-agent AI directly into Cortellis tools like Drug Discovery Intelligence, OFF-X and Competitive Intelligence, Clarivate is turning previously time-intensive R&D and market analysis tasks into higher-value,...

What Parker-Hannifin’s latest earnings and guidance signal for investors Parker-Hannifin (PH) reported fourth quarter and full year results on August 6, 2026, alongside guidance for fiscal 2027. The update combined higher recent earnings with company expectations for further sales and EPS growth. Fourth quarter sales were US$5.76b compared with US$5.24b a year earlier. Net income was US$1.09b versus US$923m. Basic EPS from continuing operations was US$8.66 compared with US$7.25, while diluted...

Lincoln Electric Holdings (LECO) has drawn fresh attention after reporting second quarter and first half 2026 results that showed higher year-on-year sales and net income, alongside continued progress on its multi year share repurchase program. See our latest analysis for Lincoln Electric Holdings. Lincoln Electric Holdings’ recent earnings update and ongoing buybacks appear to have supported sentiment, with a 14.24% 1 month share price return and a 17.73% year to date share price return. The...

Service Corporation International has delivered a 42.8% share price gain over the past three years, yet its valuation checks look mixed, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model indicating meaningful upside relative to the current US$84.40 share price. Over the last three years, Service Corporation International shares are up 42.8%, which puts recent returns in focus when judging whether the stock still offers value. Future cash flow expectations and the...